Jump to main content
Jump to site search

Issue 11, 2018
Previous Article Next Article

Discovery of potent pyruvate dehydrogenase kinase inhibitors and evaluation of their anti-lung cancer activity under hypoxia

Author affiliations

Abstract

Targeting pyruvate dehydrogenase kinases (PDKs) reverses the Warburg effect, which could be a potential therapeutic target for anti-cancer drug discovery. In this paper, we identified 12 potential PDK inhibitors by virtual ligand screening of a chemical library, and then further verified them by an enzymatic assay, in which 6, 7, and 11 strongly inhibited the function of PDKs, with IC50 values of 1.26, 0.62, and 0.41 μM against PDK1, respectively, and showed a similar inhibitory effect on PDK2, PDK3, and PDK4. However, we failed to correlate the observed inhibitory activity against PDKs with cellular activity under normal conditions. In contrast, 7 and 11 inhibited NCI-H1975 cell proliferation under hypoxia, with EC50 values of 4.66 and 3.88 μM, respectively, suggesting that 7 and 11 could be promising leads for further development of PDK inhibitors in cancer treatment.

Graphical abstract: Discovery of potent pyruvate dehydrogenase kinase inhibitors and evaluation of their anti-lung cancer activity under hypoxia

Back to tab navigation

Supplementary files

Publication details

The article was received on 10 Sep 2018, accepted on 23 Sep 2018 and first published on 24 Sep 2018


Article type: Research Article
DOI: 10.1039/C8MD00453F
Citation: Med. Chem. Commun., 2018,9, 1843-1849
  •   Request permissions

    Discovery of potent pyruvate dehydrogenase kinase inhibitors and evaluation of their anti-lung cancer activity under hypoxia

    R. Yang and C. Guo, Med. Chem. Commun., 2018, 9, 1843
    DOI: 10.1039/C8MD00453F

Search articles by author

Spotlight

Advertisements